Sarah L Pogue

US Patent:

7888484, Feb 15, 2011

Filed:

Sep 29, 2009

Appl. No.:

12/569205

Inventors:

Josephine M. Cardarelli - San Carlos CA, US
Tseng-hui Timothy Chen - Burlingame CA, US
David King - Belmont CA, US
Christopher R. Bebbington - San Mateo CA, US
Sarah Lee Pogue - Fremont CA, US
Francis J. Carr - Aberdeenshire, GB
Stephen Williams - Aberdeenshire, GB

Assignee:

Medarex, Inc. - Princeton NJ

International Classification:

C07K 16/24

US Classification:

53038823, 5303887

Abstract:

Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.

US Patent:

8268970, Sep 18, 2012

Filed:

Sep 29, 2008

Appl. No.:

12/681215

Inventors:

Jonathan A. Terrett - Sunnyvale CA, US
Sarah L. Pogue - Fremont CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Bingliang Chen - Alameda CA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/00
C12P 21/08

US Classification:

5303871, 5303873, 53038815

Abstract:

The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

US Patent:

8383779, Feb 26, 2013

Filed:

Aug 16, 2012

Appl. No.:

13/587572

Inventors:

Jonathan A. Terrett - Sunnyvale CA, US
Sarah L. Pogue - Fremont CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Bingliang Chen - Alameda CA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/00
C12P 21/08

US Classification:

5303871, 5303873, 53038815

Abstract:

The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

US Patent:

8399623, Mar 19, 2013

Filed:

Aug 16, 2012

Appl. No.:

13/587500

Inventors:

Jonathan A. Terrett - Sunnyvale CA, US
Sarah L. Pogue - Fremont CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Bingliang Chen - Alameda CA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

C07K 16/00
C12P 21/08

US Classification:

5303871, 5303873, 53038815

Abstract:

The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

US Patent:

8425904, Apr 23, 2013

Filed:

Aug 16, 2012

Appl. No.:

13/587644

Inventors:

Jonathan A. Terrett - Sunnyvale CA, US
Sarah L. Pogue - Fremont CA, US
Kristopher Toy - San Jose CA, US
Lan Yang - Morgan Hill CA, US
Bingliang Chen - Alameda CA, US

Assignee:

Bristol-Myers Squibb Company - Princeton NJ

International Classification:

A61K 39/395
A61K 39/00

US Classification:

4241301, 4241781, 4241421, 4241551

Abstract:

The present disclosure provides isolated monoclonal antibodies that specifically bind to mesothelin with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human mesothelin. In certain embodiments, the antibodies are capable of internalizing into mesothelin-expressing cells or are capable of mediating antigen dependent cellular cytotoxicity. The invention further provides anti-mesothelin antibodies that can inhibit the binding of mesothelin to the ovarian cancer antigen CA125. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting mesothelin, as well as methods for treating cancers, such as mesotheliomas, pancreatic cancers and ovarian cancers, using an anti-mesothelin antibody of this disclosure.

US Patent:

8496931, Jul 30, 2013

Filed:

Aug 10, 2007

Appl. No.:

12/377015

Inventors:

Sarah L. Pogue - Fremont CA, US
Alan J. Korman - Piedmont CA, US
Josephine M. Cardarelli - San Carlos CA, US
Mohan Srinivasan - Cupertino CA, US
Bingliang Chen - Alameda CA, US
Alasdair F. Bell - Mountain View CA, US

Assignee:

Medarex, Inc. - Princeton NJ
Ono Pharmaceutical Co., Ltd. - Osaka

International Classification:

A61K 39/395

US Classification:

4241301, 5303871

Abstract:

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to SDF-1 with high affinity. Nucleic acid molecules encoding SDF-1 antibodies, expression vectors, host cells and methods for expressing the SDF-1 antibodies are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the SDF-1 antibodies are also provided. Methods for detecting SDF-1, as well as methods for treating various B cell malignancies, including breast cancer, multiple myeloma and non-Hodgkin's lymphoma, and autoimmune disorders are disclosed.

US Patent:

20050208041, Sep 22, 2005

Filed:

Apr 23, 2004

Appl. No.:

10/831459

Inventors:

Josephine Cardarelli - San Carlos CA, US
Tseng-hui Chen - Burlingame CA, US
David King - Belmont CA, US
Christopher Bebbington - San Mateo CA, US
Sarah Pogue - Fremont CA, US
Francis Carr - Aberdeenshire, GB
Stephen Williams - Aberdeenshire, GB

Assignee:

Medarex, Inc. - Princeton NJ

International Classification:

A61K039/395
C07K016/44

US Classification:

424141100, 530388150

Abstract:

Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.

US Patent:

20110086422, Apr 14, 2011

Filed:

Dec 20, 2010

Appl. No.:

12/972813

Inventors:

Josephine M. Cardarelli - San Carlos CA, US
Tseng-hui Timothy Chen - Burlingame CA, US
David King - Belmont CA, US
Christopher R. Bebbington - San Mateo CA, US
Sarah Lee Pogue - Fremont CA, US
Francis J. Carr - Aberdeenshire, GB
Stephen Williams - Aberdeenshire, GB

International Classification:

C12N 5/071

US Classification:

435325

Abstract:

Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.